CEO and Co-founder buys shares
Hemogenyx Pharmaceuticals Plc (LSE: HEMO), the biotechnology company developing novel therapies to transform bone marrow, or blood stem cell, transplantation for the treatment of blood diseases, announces that on 5 February 2018 Dr Vladislav Sandler, Chief Executive Officer and Co-Founder of the Company, purchased 26,800 ordinary shares of £0.01 in the Company (“Ordinary Shares”) at a price of 2.37 pence per Ordinary Share.
Following this transaction, Dr Sandler now holds 40,478,010 Ordinary Shares, representing approximately 11.37% of the Company’s issued share capital.
The Notification of Dealing Forms provided in accordance with the requirements of MAR in relation to the transactions listed above are set out below:
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them
| 1 | Details of the person discharging managerial responsibilities / person closely associated | ||||
| a) | Name | Vladislav Sandler | |||
| 2 | Reason for the notification | ||||
| a) | Position/status | Chief Executive Officer and Co-Founder | |||
| b) | Initial notification /Amendment | Initial notification | |||
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
| a) | Name | Hemogenyx Pharmaceuticals Plc | |||
| b) | LEI | n/a | |||
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||||
| a) | Description of the financial instrument, type of instrument | Ordinary shares of £0.01 each | |||
| Identification code | ISIN GB00BYX3WZ24 | ||||
| b) | Nature of the transaction | Purchase of Ordinary Shares | |||
| c) | Price(s) and volume(s) | ||||
| Price(s) | Volume(s) | ||||
| 2.37p | 26,800 | ||||
| d) | Aggregated information | ||||
| – Aggregated volume | N/A – single transaction | ||||
| – Price | |||||
| e) | Date of the transaction | 5 February 2018 | |||
| f) | Place of the transaction | London Stock Exchange | |||
Enquiries:
| Hemogenyx Pharmaceuticals Limited | www.hemogenyx.com |
| Dr Vladislav Sandler, Chief Executive Officer & Co-Founder | Via Walbrook PR |
| Dr Robin Campbell, Chairman | |
| Optiva Securities Ltd | Tel: +44 (0)20 3137 1902 |
| Christian Dennis | |
| Shard Capital Partners LLP | Tel: +44 (0)20 7186 9950 |
| Damon Heath, Erik Woolgar | |
| Peterhouse Corporate Finance Limited | Tel: +44 (0)20 7469 0930 |
| Lucy Williams/Duncan Vasey | |
| Walbrook PR (UK Media & Investor Relations) | Tel: +44 (0)20 7933 8780 or hemogenyx@walbrookpr.com |
| Paul McManus | Mob: +44 (0)7980 541 893 |
| US Media enquiries | |
| Lowell Goodman | Tel: +1 (323) 646-3249 or lowell@lowellgoodman.net |
About Hemogenyx Pharmaceuticals Plc
Hemogenyx Pharmaceuticals Plc is a publicly traded company (LSE: HEMO) headquartered in London, with its wholly owned U.S. operating subsidiary, HemoGenyx LLC, located in its state-of-the-art research facility in Brooklyn, New York.
HemoGenyx is a preclinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapies and treatments for blood diseases such as leukemia and lymphoma. The company’s leading technologies aim to change the way in which bone marrow/hematopoietic stem cell (BM/HSC) transplants are performed and improve their efficacy. HemoGenyx’s two distinct and complementary products include an immunotherapy product for patient conditioning–the CDX bi-specific antibody–and a cell therapy product for BM/HSC transplantation–the HuPHEC. Each of these products holds the potential to revolutionize the way BM/HSC transplants are being performed, offering solutions that mitigate the dangers and limitations associated with the current standard of care.
For more information, visit www.hemogenyx.com.